Research programme: antiarrhythmic agents - sanofi-aventisAlternative Names: SAR114646; SAR114646A
Latest Information Update: 03 Sep 2008
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class Antiarrhythmics
- Mechanism of Action L-type calcium channel antagonists; Potassium channel antagonists; Sodium channel antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Arrhythmias